78,442 Shares in Pfizer Inc. $PFE Bought by Coastal Bridge Advisors LLC

Coastal Bridge Advisors LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 78,442 shares of the biopharmaceutical company's stock, valued at approximately $1,889,000.

A number of other large investors have also added to or reduced their stakes in PFE. Handelsbanken Fonder AB lifted its holdings in shares of Pfizer by 10.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company's stock valued at $59,295,000 after purchasing an additional 232,528 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of Pfizer by 15.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company's stock worth $132,365,000 after purchasing an additional 745,213 shares in the last quarter. Leuthold Group LLC purchased a new position in Pfizer during the 2nd quarter worth $4,887,000. North Dakota State Investment Board acquired a new position in Pfizer during the 4th quarter valued at about $5,348,000. Finally, Park National Corp OH raised its stake in Pfizer by 332.1% in the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company's stock valued at $5,829,000 after buying an additional 186,053 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 1.0%

Pfizer stock opened at $28.00 on Friday. The stock has a 50-day moving average price of $25.49 and a 200 day moving average price of $26.29. The company has a market capitalization of $159.62 billion, a price-to-earnings ratio of 36.85 and a beta of 0.34. Pfizer Inc. has a 52 week low of $23.58 and a 52 week high of $28.75. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the company earned $0.78 EPS. Pfizer's quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. Pfizer's dividend payout ratio is presently 226.32%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Guggenheim dropped their price target on Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. HSBC lowered shares of Pfizer from a "buy" rating to a "hold" rating and decreased their price objective for the company from $32.00 to $28.00 in a research report on Monday, July 6th. Bank of America lowered their target price on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research note on Friday, July 10th. JPMorgan Chase & Co. dropped their target price on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a research report on Wednesday, July 8th. Finally, Wolfe Research restated an "underperform" rating and set a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $28.28.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COVID-19 vaccine. The updated Comirnaty formula is intended for adults 65 and older and younger individuals with qualifying health risks, with shipments beginning immediately. The approval supports Pfizer’s ability to compete in the upcoming respiratory-virus season and could provide seasonal revenue support. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
• Positive Sentiment: The FDA also approved updated COVID-19 vaccines from Moderna and Novavax-Sanofi, following guidance to target the dominant XFG variant. Pfizer’s immediate distribution and extensive real-world safety record may help preserve its position in the U.S. vaccine market, although demand remains difficult to forecast. US FDA approves updated COVID vaccines for 2026-27 season

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source